CIK 0001919246 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Pelthos Therapeutics Inc.
Sign in to watch- Ticker
- PTHS
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 863335449
- Phone
- 919-908-2422
- Business address
- 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM, NC, 27703
- Former names
- Channel Therapeutics Corp, Chromocell Therapeutics Corp
- 4 Planned sale Director sold 786 shares at an average $20.92 ($16,439)
- 4 Planned sale Director sold 797 shares at an average $20.92 ($16,670)
- 4/A Grant or award Director acquired 28,012 shares (grant or award)
- 4/A Grant or award Director acquired 36,969 shares (grant or award)
- 4/A Grant or award Director acquired 28,012 shares (grant or award)
- 4/A Grant or award CEO and President acquired 83,678 shares (grant or award)
- 4/A Grant or award Director acquired 25,478 shares (grant or award)
- 4/A Grant or award Director acquired 25,478 shares (grant or award)
- 4/A Grant or award Chief Commercial Officer acquired 30,518 shares (grant or award)
- 4/A Grant or award Director acquired 19,108 shares (grant or award)
- 4/A Grant or award CFO, Treas & Secty acquired 33,472 shares (grant or award)
- 8-K Event Results of operations · Regulation FD disclosure
- 10-K Report Annual Report
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 424B3 Offering Prospectus
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- S-3 Offering Registration Statement
Page 3 of 13 · 258 filings